PASG - Passage Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.59
-0.59 (-3.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close15.18
Open14.97
Bid13.50 x 800
Ask16.30 x 800
Day's Range14.59 - 15.80
52 Week Range8.09 - 23.25
Volume145,369
Avg. Volume491,403
Market Cap668.197M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.50
  • GlobeNewswire

    Passage Bio to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

    PHILADELPHIA, March 27, 2020 -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous.

  • GlobeNewswire

    Passage Bio Announces Exercise of Underwriters’ Option to Purchase Additional Shares

    PHILADELPHIA, March 09, 2020 -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous.

  • GlobeNewswire

    Passage Bio Appoints Athena Countouriotis to Board of Directors

    Passage Bio, Inc. (PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced the appointment of Athena Countouriotis to its board of directors. “We are immensely excited to have Athena join our board of directors,” said Dr. Bruce Goldsmith, chief executive officer of Passage Bio. “Her public company operations leadership, deep clinical development expertise and salient gene therapy experience will provide tremendous support to Passage Bio as we move forward as a newly publicly traded company and advance our lead programs into clinical development starting in the second half of 2020.”

  • GlobeNewswire

    Passage Bio Announces Pricing of Initial Public Offering

    PHILADELPHIA, Feb. 27, 2020 -- Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system.